Fingerprint
Dive into the research topics of 'Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): Survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically